Series A · Biotech · Charleroi, Belgium · 5–10 employees
Bioxodes is a Gosselies (Wallonia) clinical-stage biotech developing first-in-class therapeutics targeting thrombo-inflammation to address huge unmet needs such as hemorrhagic stroke and related conditions; its lead asset BIOX-101 — derived from a tick-saliva protein — uniquely inhibits key coagulation factors and neutrophil activation without increasing bleeding risk, with promising Phase 2a interim data and plans for Phase 2b pivotal trials that could transform stroke care.